Cellular uptake and antitumor activity of the now anthracycline analog DA-125 in human cancer cell lines

Cancer Chemotherapy and Pharmacology

Volumn 40, Issue 1, 1997, Pages 23-30

  Lim, Kyoung Hwa ^a   Kim, Hun Sik ^b   Yang, Yong Man ^a   Lee, Sang Deuk ^c   Kim, Won Bae ^c   Yang, Junnick ^c   Park, Jae Gahb ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Chungbuk National University College of Medicine   (South Korea)

^c Dong A Pharmaceutical Company   (South Korea)

Author keywords

Cellular uptake; Cross resistance; DA 125; Doxorubicin analog; MTT test; Multidrug resistance

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DOXORUBICIN; DRUG METABOLITE; GALARUBICIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG METABOLISM; DRUG UPTAKE; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; DRUG RESISTANCE; HUMANS; P-GLYCOPROTEIN; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0030941010     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050620     Document Type: Article

References (34)

1. Ahn BO, Baik NG, Lee SB, Kim WB, Yang J, Kim PY, Kim DB, Lee JK (1993) Local irritation of DA-125. Korean J Appl Pharmacol 1: 20
2. Ahn BO, Baik NG, Kim OJ, Kang KK, Lee SB, Kim WB, Yang J, Ko KH (1993) Hematotoxicity and vascular irritation of DA-125, a new anthracycline anticancer agent. Korean J Appl Pharmacol 2: 244
3. Baik NG, Ahn BO, Lee SB, Kim WB, Yang J, Watanabe T (1993) A study on cardiotoxicity of DA-125, a new anticancer antibiotic. Korean J Appl Pharmacol 1: 9
4. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB (1987) Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47: 936
5. Carter SK (1975) Adriamycin - a review. J Natl Cancer Inst 55: 1265
6. Chirgwin JM, Przybyla AE, Macdonald RJ, Rutter WJ (1979) Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18: 5294
7. Doroshow JH (1991) Doxorubicin-induced cardiac toxicity (editiorial; comment). N Engl J Med 324: 843
8. Goldstein L, Galski H, Fojo A, Willingham M, Lai S-H, Gazdar A, Priker R, Green A, Crist W, Brodeur G, Grant C, Lieber M, Cossman J, Gottesman MM, Pastan I (1989) Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81: 116-124
9. Iigo M, Nishikata K, Nakajima Y, Hoshi A, Kadosawa H, Nakajima S (1990) Therapeutic activity and tissue distribution of ME2303, a new anthracycline containing fluorine, and its metabolites in mice bearing hepatic metastases of Lewis lung carcinoma. Anticancer Drugs 1: 77
10. Iigo M, Hoshi A, Kadosawa H, Fujigaki M (1991) Antitumor activity and metabolism of a new anthracycline-containing fluorine (ME2303) in Lewis lung carcinoma-bearing mice. Jpn J Cancer Res 82: 1317
11. Inaba M, Kobayashi H, Sakurai Y, Johnson RK (1979) Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia. Cancer Res 39: 2200
12. Kitaura K, Watanabe Y, Ishihara Y, Takahira H (1972) Antitumor activity of adriamycin. J Antibiot (Tokyo) 25: 65
13. Kruh GD, Goldstein LJ (1993) Doxorubicin and multidrug resistance. Curr Opin Oncol 5: 1029
14. Kunimoto S, Miura K, Takahashi Y, Takeuchi T, Umezawa H (1983) Rapid uptake by cultured tumor cells and intracellular behavior of 4′-O-tetrahydropyranyladriamycin. J Antibiot (Tokyo) 36: 312
15. Kunimoto S, Miura K, Umezawa K, Xu CZ, Masuda T, Takeuchi T, Umezawa H (1984) Cellular uptake, efflux and cytostatic activity of 4′-O-tetrahydropyranyladriamycin in adriamycin-sensitive and resistant tumor cell lines. J Antibiot (Tokyo) 37: 1697
16. Kunimoto S, Komuro K, Nosaka C, Tsuchiya T, Fukatsu S, Takeuchi T (1990) Biological activities of new anthracyclines containing fluorine, FAD104 and its metabolites. J Antibiot (Tokyo) 43: 556
17. Lee SD, Park JB, Lee WI, Shim HJ, Lee ED, Lee JJ, Kim WB, Yang J, Kim CK, Lee MG (1995) Pharmacokinetics and antitumor activity of a new anthracycline, DA-125, after intravenous administration of subcutaneously implanted Lewis lung carcinoma-bearing mice. Biopharm Drug Dispos 16: 489
18. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55
19. Omoto S, Kondo S, Fukatsu S, Takeuchi T, Umezawa K, Tsuchiya T, Umezawa S (1988) Biological properties of ME2303 (FAD-104), a new anthracycline. Drugs Exp Clin Res 14: 435
20. Park JG, Kramer BS, Steinberg SM, Carmichael J, Collins JM, Minna JD, Gazdar AF (1987) Chemosensitivity testing of human colorectal carcinoma cell lines using a tetrazolium-based colorimetric assay. Cancer Res 47: 5875
21. Park JG, Oie HK, Sugarbaker HK, Henslee JG, Chen TR, Johnson BE, Gazdar AF (1987) Characteristics of cell lines established from human colorectal carcinoma. Cancer Res 47: 6710
22. Park JG, Frucht H, LaRocca RV, Bliss DPJ, Kurita Y, Chen TR, Henslee JG, Trepel JB, Jensen RT, Johnson BE, Bang YJ, Kim JP, Gazdar AF (1990) Characteristics of cell lines established from human gastric carcinoma. Cancer Res 50: 2773
23. Park JG, Kramer BS, Lai SL, Goldstein LJ, Gazdar AF (1990) Chemosensitivity patterns and expression of human multidrug resistance-associated MDR1 gene by human gastric and colorectal carcinoma cell lines. J Natl Cancer Inst 82: 193
24. Park JG, Lee SK, Hong IG, Kim HS, Lim KH, Choe KJ, Kim WH, Kim YI, Tsuruo T, Gottesman MM (1994) MDR1 gene expression: its effect on drug resistance to doxorubicin in human hepatocellular carcinoma cell lines. J Natl Cancer Insy 86: 700
25. Park JG, Lee JH, Kang MS, Park KJ, Jeon YM, Lee HJ, Kwon HS, Park HS, Yeo KS, Lee KU, Kim ST, Chung JK, Hwang YJ, Lee HS, Kim CY, Lee YI, Chen TR, Hay RJ, Song SY, Kim WH, Kim CW, Kim YI (1995) Characterization of cell lines established from human hepatocellular carcinoma. Int J Cancer 62: 276
26. Pastan I, Gottesman MM (1991) Multidrug resistance. Annu Rev Med 42: 277
27. Shim HJ, Lee ED, Yoon EJ, Lee SD, Kim WB, Yang J, Lee MG (1994) Pharmacokinetics of FT-ADM after intravenous administration of DA-125, a prodrug of FT-ADM or FT-ADM to rats. A new adriamycin analog containing fluorine. Int J Pharm 103: 147
28. Shim HJ, Lee ED, Yoon EJ, Lee SD, Kim WB, Yang J, Lee MG (1994) Simultaneous determination of a new anthracycline, DA-125, and its metabolites M1, M2, M3 and M4 in plasma and urine by high-performance liquid chromatography. J Chromatogr 656: 407
29. Son MW, Roh JK, Kim WB, Yang J, Kim BS (1994) Mechanism of antitumor activity of DA-125, a new anthracycline antibiotic (I). J Korean Cancer Assoc 26: 127
30. Tsuchiya T, Takagi Y, Ok K Umezawa S, Takeuchi T, Wako N, Umezawa H (1986) Synthesis and antitumor activities of 7-O-(2,6-dideoxy-2-fluoro-α-L-talopyranosyl)daunomycinone and -adriamycinone. J Antibiot (Tokyo) 39: 731
31. Tsuchiya T, Takagi Y, Umezawa S, Takeuchi T, Komuro K, Nosaka C, Umezawa H, Fukatsu S, Yoneta T (1988) Synthesis and antitumor activity of 14-O-acyl derivatives of 7-O-(2,6-dideoxy-2-fluoro-α-L-talopyranosyl)adriamycin. J Antibiot (Tokyo) 41: 988
32. Tsuruo T, Yusa K, Sudo Y, Takamori R, Sugimoto Y (1989) A fluorine-containing anthracycline (ME2303) as a new antitumor agent against m urine and human tumors and their multidrug-resistant sublines. Cancer Res 49: 5537
33. Ueda K, Clark DP, Chen CJ, Roninson IB, Gottesman MM, Pastan I (1991) The human multidrug resistance (mdr 1) gene, cDNA cloning and transcription initiation. J Biol Chem 262: 505
34. Yoon EJ, Lee ED, Yoon WH, Shim HJ, Lee SD, Kim WB, Yang J, Lee MG (1994) Pharmacokinetics, tissue distribution and biliary excretion of FT-ADM after intravenous administration of DA-125, a prodrug of FT-ADM, to dogs. A new adriamycin analog containing fluorine. Int J Pharm 109: 1814